Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 3, 2010, Pages 239-247

  Adi, Handoko ^a   Young, Paul M ^a   Chan, Hak Kim ^a   Agus, Helen ^a   Traini, Daniela ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antibiotics; Ciprofloxacin; Cystic fibrosis; Dry powder inhaler (DPI); Mannitol; Mucolytics

Indexed keywords

CIPROFLOXACIN; MANNITOL;

AEROSOL; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CHEMICAL ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLLOIDAL FORCE MICROSCOPY; CONTROLLED STUDY; CYSTIC FIBROSIS; DIFFERENTIAL SCANNING CALORIMETRY; DISK DIFFUSION; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; DRY POWDER; DYNAMIC VAPOR SORPTION; ELECTRON MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INHALATION; LASER DIFFRACTION; MOISTURE; MOLECULAR DYNAMICS; MUCOCILIARY CLEARANCE; PARTICLE SIZE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; THERMODYNAMICS; X RAY POWDER DIFFRACTION;

ADMINISTRATION, INHALATION; ANTI-INFECTIVE AGENTS; CHEMISTRY, PHARMACEUTICAL; CIPROFLOXACIN; CYSTIC FIBROSIS; DRUG COMBINATIONS; HUMANS; MANNITOL; MICROBIAL SENSITIVITY TESTS; NEBULIZERS AND VAPORIZERS; POWDERS; PSEUDOMONAS AERUGINOSA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES;

EID: 77953021975     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.03.020     Document Type: Article

References (67)

1. Abbott J., Hart A. Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical review. Health Qual. Life Outcomes 2005, 3:19.
2. Adi H., Young P.M., Chan H.K., Salama R., Traini D. Controlled release antibiotics for dry powder lung delivery. Drug Dev. Ind. Pharm. 2009.
3. Adi H., Young P.M., Chan H.K., Stewart P., Agus H., Traini D. Cospray dried antibiotics for dry powder lung delivery. J. Pharm. Sci. 2008, 97:3356-3366.
4. Adi H., Young P.M., Chan H.K., Stewart P., Agus H., Traini D. Cospray dried antibiotics for dry powder lung delivery. J. Pharm. Sci.-Us. 2008, 97:3356-3366.
5. Anderson G. A clinical trial of a mucolytic agent - acetylcysteine - in chronic bronchitis. Br. J. Dis. Chest 1966, 60:101-103.
6. Anderson S.D., Brannan J., Spring J., Spalding N., Rodwell L.T., Chan K., Gonda I., Walsh A., Clark A.R. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am. J. Resp. Crit. Care 1997, 156:758-765.
7. Armstrong D.S., Grimwood K., Carlin J.B., Carzino R., Gutierrez J.P., Hull J., Olinsky A., Phelan E.M., Robertson C.F., Phelan P.D. Lower airway inflammation in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 1997, 156:1197-1204.
8. Bosquillon C., Lombry C., Preat V., Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release 2001, 70:329-339.
9. Bradley J.M., Moran F.M., Elborn J.S. Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews. Resp. Med. 2006, 100:191-201.
10. Budavari Z., Zelko R., Racz I., Marton S. Compatibility study between folic acid, vitamin B6 and tablet excipients using differential scanning calorimetry. Pharmazie 1999, 54:861-862.
11. Burger A., Henck J.-O., Hetz S., Rollinger J.M., Weissnicht A.A., Stöttner H. Energy/temperature diagram and compression behavior of the polymorphs of mannitol. J. Pharm. Sci. 2000, 89:457-468.
12. Buzzetti R., Salvatore D., Baldo E., Forneris M.P., Lucidi V., Manunza D., Marinelli I., Messore B., Neri A.S., Raia V., Furnari M.L., Mastella G. An overview of international literature from cystic fibrosis registries. 1. Mortality and survival studies in cystic fibrosis. J. Cyst. Fibros. 2009, 8:229-237.
13. Bye P.T.P., Elkins M.R. Other mucoactive agents for cystic fibrosis. Paediatr. Resp. Rev. 2007, 8:30-39.
14. Cazzola M., Donner C.F., Hanania N.A. One hundred years of chronic obstructive pulmonary disease (COPD). Resp. Med. 2007, 101:1049-1065.
15. Cazzola M., Hanania N.A., Jones P.W., Mahler D.A., Make B., Ohar J., Rennard S. It's about time-directing our attention toward modifying the course of COPD. Resp. Med. 2008, 102(Suppl 1):S37-48.
16. Chew N.Y., Chan H.K. Use of solid corrugated particles to enhance powder aerosol performance. Pharm. Res. 2001, 18:1570-1577.
17. Conley J., Yang H.M., Wilson T., Blasetti K., DiNinno V., Schnell G., Wong J.P. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob. Agents Chemother. 1997, 41:1288-1292.
18. Corey M., Mclaughlin F.J., Williams M., Levison H. A comparison of survival, growth, and pulmonary-function in patients with cystic-fibrosis in Boston and Toronto. J. Clin. Epidemiol. 1988, 41:583-591.
19. Daviskas E., Anderson S.D., Brannan J.D., Chan H.K., Eberl S., Bautovich G. Inhalation of dry-powder mannitol increases mucociliary clearance. Eur. Resp. J. 1997, 10:2449-2454.
20. Daviskas E., Anderson S.D., Eberl S., Chan H.K., Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. J. Resp. Crit. Care Med. 1999, 159:1843-1848.
21. Daviskas E., Anderson S.D., Eberl S., Chan H.K., Young I.H. The 24-h, effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 2001, 119:414-421.
22. Daviskas E., Anderson S.D., Gomes K., Briffa P., Cochrane B., Chan H.K., Young I.H., Rubin B.K. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005, 10:46-56.
23. Decramer M., Rutten-van Molken M., Dekhuijzen P.N., Troosters T., van Herwaarden C., Pellegrino R., van Schayck C.P., Olivieri D., Del Donno M., De Backer W., Lankhorst I., Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005, 365:1552-1560.
24. Deterding R., Retsch-Bogart G., Milgram L., Gibson R., Daines C., Zeitlin P.L., Milla C., Marshall B., Lavange L., Engels J., Mathews D., Gorden J., Schaberg A., Williams J., Ramsey B. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr. Pulmonol. 2005, 39:339-348.
25. Donaldson S.H., Bennett W.D., Zeman K.L., Knowles M.R., Tarran R., Boucher R.C. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med. 2006, 354:241-250.
26. Doring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J. Cyst. Fibros. 2004, 3:67-91.
27. Finlay W.H., Wong J.P. Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin. Int. J. Pharm. 1998, 167:121-127.
28. Fitzgeorge R.B., Baskerville A., Featherstone A.S.R. Treatment of experimental legionnaires-disease by aerosol administration of rifampicin, ciprofloxacin, and erythromycin. Lancet 1986, 1:502-503.
29. Goldberg H.J., Deykin A. Advances in lung transplantation for patients who have cystic fibrosis. Clin. Chest Med. 2007, 28:445.
30. Grasemann H., Stehling F., Brunar H., Widmann R., Laliberte T.W., Molina L., Doring G., Ratjen F. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 2007, 131:1461-1466.
31. Heaf D.P., Webb G.J., Matthew D.J. In vitro assessment of combined antibiotic and mucolytic treatment for Pseudomonas aeruginosa infection in cystic fibrosis. Arch. Dis. Child. 1983, 58:824-826.
32. Heijerman H., Westerman E., Conway S., Touw D. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J. Cyst. Fibros. 2009, 8:295-315.
33. Hordvik N.L., Konig P., Morris D., Kreutz C., Barbero G.J. A longitudinal-study of bronchodilator responsiveness in cystic-fibrosis. Am. Rev. Resp. Dis. 1985, 131:889-893.
34. Hulse W.L., Forbes R.T., Bonner M.C., Getrost M. The characterization and comparison of spray-dried mannitol samples. Drug Dev. Ind. Pharm. 2009, 35:712-718.
35. Jones A.P., Wallis C.E. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst. Rev. 2003, CD001127.
36. Kellerman D., Rossi Mospan A., Engels J., Schaberg A., Gorden J., Smiley L. Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. Pulm. Pharmacol Ther. 2008, 21:600-607.
37. Kerem E., Corey M., Gold R., Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J. Pediatr. 1990, 116:714-719.
38. Kim A.I., Akers M.J., Nail S.L. The physical state of mannitol after freeze-drying: effects of mannitol concentration, freezing rate, and a noncrystallizing cosolute. J. Pharm. Sci. 1998, 87:931-935.
39. Knechtel S.A., Klepser M.E. Safety of aerosolized amphotericin B. Expert Opin. Drug Saf. 2007, 6:523-532.
40. Konstan M.W., Byard P.J., Hoppel C.L., Davis P.B. Effect of high-dose ibuprofen in patients with cystic-fibrosis. N. Engl. J. Med. 1995, 332:848-854.
41. Konstan M.W., Hilliard K.A., Norvell T.M., Berger M. Bronchoalveolar lavage findings in cystic-fibrosis patients with stable, clinically mild lung-disease suggest ongoing infection and inflammation. Am. J. Resp. Crit. Care 1994, 150:448-454.
42. Lands L.C., Milner R., Cantin A.M., Manson D., Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J. Pediatr. 2007, 151:249-254.
43. Lawson D., Saggers B.A. N.A.C. and antibiotics in cystic fibrosis. Br. Med. J. 1965, 1:317.
44. Master K. Spray Drying Handbook 1979, Halsted Press, London.
45. Matsui H., Grubb B.R., Tarran R., Randell S.H., Gatzy J.T., Davis C.W., Boucher R.C. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998, 95:1005-1015.
46. Millar A.B., Pavia D., Agnew J.E., Lopez-Vidriero M.T., Lauque D., Clarke S.W. Effect of oral N-acetylcysteine on mucus clearance. Br. J. Dis. Chest 1985, 79:262-266.
47. O'Sullivan B.P., Freedman S.D. Cystic fibrosis. Lancet 2009, 373:1891-1904.
48. Orenstein D.M. Long-term inhaled bronchodilator therapy in cystic-fibrosis. Chest 1991, 99:1061-11061.
49. Pamukcu A., Bush A., Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr. Pulmonol. 1995, 19:10-15.
50. Reas H.W. The effect of N-acetylcysteine on the viscosity of tracheobronchial secretions in cystic fibrosis of the pancreas. J. Pediatr. 1963, 62:31-35.
51. Regelmann W.E., Elliott G.R., Warwick W.J., Clawson C.C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung-function in cystic-fibrosis more than do bronchodilators and chest physiotherapy alone. Am. Rev. Resp. Dis. 1990, 141:914-921.
52. Roberts D., Cole P. N-acetylcysteine potentiates the anti-pseudomonas activity of carbenicillin in vitro. J. Infect. 1981, 3:353-359.
53. Robinson M., Daviskas E., Eberl S., Baker J., Chan H.K., Anderson S.D., Bye P.T. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur. Respir. J. 1999, 14:678-685.
54. Robinson M., Daviskas E., Eberl S., Baker J., Chan H.K., Anderson S.D., Bye P.T.P. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur. Respir. J. 1999, 14:678-685.
55. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., Coquillette S., Fieberg A.Y., Accurso F.J., Campbel P.W., Grp M.S. Azithromycin in, patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa-a randomized controlled trial. J. Am. Med. Assoc. 2003, 290:1749-1756.
56. Schwarz C., Mehnert W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int. J. Pharm. 1997, 157:171-179.
57. Serisier D.J., Shute J.K., Hockey P.M., Higgins B., Conway J., Carroll M.P. Inhaled heparin in cystic fibrosis. Eur. Respir. J. 2006, 27:354-358.
58. Shak S., Capon D.J., Hellmiss R., Marsters S.A., Baker C.L. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:9188-9192.
59. Smith A.L., Ramsey B.W., Hedges D.L., Hack B., Williamswarren J., Weber A., Gore E.J., Redding G.J. Safety of aerosol tobramycin administration for 3 months to patients with cystic-fibrosis. Pediatr. Pulmonol. 1989, 7:265-271.
60. N.C.C.L. Performance standards for antimicrobial disk susceptibility test. Approved Standard M2-A6 1996, NCCLS, Wayne, PA.
61. Swierzewski S.J. Cystic fibrosis: lung treatment. Pulmonologychannel 2000, Your Pulmonology Community.
62. Tang P., Chan H.K., Chiou H., Ogawa K., Jones M.D., Adi H., Buckton G., Prud'homme R.K., Raper J.A. Characterisation and aerosolisation of mannitol particles produced via confined liquid impinging jets. Int. J. Pharm. 2009, 367:51-57.
63. Traini D., Young P.M. Delivery of antibiotics to the respiratory tract: an update. Expert Opin. Drug Deliv. 2009, 6:897-905.
64. Wark P.A., McDonald V., Jones A.P. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst. Rev. 2005, CD001506.
65. Young P.M., Price R., Tobyn M.J., Buttrum M., Dey F. The influence of relative humidity on the cohesion properties of micronized drugs used in inhalation therapy. J. Pharm. Sci.-Us. 2004, 93:753-761.
66. Young P.M., Price R., Tobyn M.J., Buttrum M., Dey F. Investigation into the effect of humidity on drug-drug interactions using the atomic force microscope. J. Pharm. Sci. 2003, 92:815-822.
67. Zahm J.M., Girod de Bentzmann S., Deneuville E., Perrot-Minnot C., Dabadie A., Pennaforte F., Roussey M., Shak S., Puchelle E. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus. Eur. Resp. J. 1995, 8:381-386.